In Brief | Published:

PAEDIATRIC RHEUMATOLOGY

Recombinant IL-1Ra as first-line therapy in sJIA

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

    Original article

    1. ter Haar, N. M. et al. Treat-to-target using first-line recombinant interleukin-1 receptor antagonist monotherapy in new-onset systemic juvenile idiopathic arthritis: results from a five year follow-up study. Arthritis Rheumatol. https://doi.org/10.1002/art.40865 (2019)

    Download references

    Author information

    Correspondence to Joanna Collison.

    Rights and permissions

    Reprints and Permissions

    About this article

    Verify currency and authenticity via CrossMark